Vir Biotechnology Inc (VIR)

$4.86 +0.07 (1.46%)
Market Cap 694.58M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 635,259
Avg Vol 1,295,832
Day's Range N/A - N/A
Shares Out 138.92M
Stochastic %K 17%
Beta 1.28
Analysts Strong Sell
Price Target $17.22

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
highnihilism
highnihilism Sep. 16 at 7:44 PM
IWM: Russell 2000 → $REFI Chicago Atlantic Real Estate Finance $PLOW Douglas Dynamics $INBX Inhibrx Biosciences $VIR Vir Biotechnology $RXST Rxsight
0 · Reply
highnihilism
highnihilism Sep. 16 at 3:03 PM
Biotech → $KRYS Krystal Biotech $NTRA Natera $MYGN Myriad Genetics $VIR Vir Biotechnology $TWST Twist Bioscience
0 · Reply
justme_DC
justme_DC Sep. 15 at 6:30 PM
$VIR Ugly price action today. But interesting (yes, I know just one small piece of many) is the nice inflow vs. outflow and that 17 DTC on Fintel. Time will tell, could be a nice set up.
0 · Reply
Njdude
Njdude Sep. 12 at 7:10 PM
$VIR I just realized that we got fast track designation in June of 2024 so we are in our 15 month already. Google search said it takes 1 to 3 years for phase 3 trials but I couldn’t find anything on how long it takes with fast track. Either way we are almost half way to 3 years. Let’s hope for some good news soon.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 10 at 4:19 PM
$VIR we are actually up month to date by 20%, it would be nice to recover at 20% a month, imagine the effect of compounding at that rate.
0 · Reply
Njdude
Njdude Sep. 10 at 12:13 AM
$VIR anyone know how the fireside chat went today ?
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 8 at 10:41 AM
$VIR let’s smash $6 this week, we are definitely trying to build at the moment. I read yesterday about meme stocks such as Gamestore are starting to shoot up again, basically Reddit identifies stocks which are heavily shorted and advises it’s members to start buying & then the shorters have to close their positions creating massive bounces of up to 1200%. It happened to Vir years ago when the Reddit brigade & Robin Hood started buying up our shares & in minutes our price went up to $140 before quickly settling back, lets hope history repeats itself.
1 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 9:03 PM
$VIR SAN FRANCISCO, August 25, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. Just a reminder that Vir have used conferences in the past when releasing data.
0 · Reply
Mhand
Mhand Sep. 4 at 1:47 PM
$VIR And here comes the blatant manipulation.
1 · Reply
PCIntern
PCIntern Sep. 4 at 1:28 PM
$VIR in the past I have found that when you get this type of almost-surreptitious increase in the SP after months or years of moribund performance, you find out after the fact that “somebody knew something”. Here’s hoping….
0 · Reply
Latest News on VIR
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 4:05 PM EDT - 22 days ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:01 PM EDT - 5 weeks ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Aug 6, 2025, 8:05 AM EDT - 5 weeks ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 6 weeks ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 24, 2025, 8:05 AM EDT - 7 weeks ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 23, 2025, 12:10 PM EDT - 7 weeks ago

Vir Biotechnology: Hep B And Cancer Projects March On

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 3 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025, 6:00 AM EDT - 4 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025, 3:37 PM EDT - 4 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 4 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 24, 2025, 9:30 AM EDT - 5 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 21, 2025, 7:10 AM EDT - 6 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Mar 13, 2025, 8:05 AM EDT - 6 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 7 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 8 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 10, 2025, 2:32 PM EST - 8 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 8 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 12:28 PM EST - 8 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Jan 8, 2025, 7:45 AM EST - 8 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 9:30 AM EST - 9 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 13, 2024, 12:57 PM EST - 9 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 12, 2024, 4:05 PM EST - 9 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 26, 2024, 9:30 AM EST - 10 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 9:30 AM EST - 10 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 9:15 PM EST - 10 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 18, 2024, 4:05 PM EST - 10 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 15, 2024, 11:00 AM EST - 10 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 5, 2024, 11:29 AM EST - 11 months ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:12 PM EDT - 11 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 4:05 PM EDT - 11 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 17, 2024, 4:30 PM EDT - 11 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 3, 2024, 4:00 PM EDT - 1 year ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 10, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:10 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:02 PM EDT - 1 year ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

highnihilism
highnihilism Sep. 16 at 7:44 PM
IWM: Russell 2000 → $REFI Chicago Atlantic Real Estate Finance $PLOW Douglas Dynamics $INBX Inhibrx Biosciences $VIR Vir Biotechnology $RXST Rxsight
0 · Reply
highnihilism
highnihilism Sep. 16 at 3:03 PM
Biotech → $KRYS Krystal Biotech $NTRA Natera $MYGN Myriad Genetics $VIR Vir Biotechnology $TWST Twist Bioscience
0 · Reply
justme_DC
justme_DC Sep. 15 at 6:30 PM
$VIR Ugly price action today. But interesting (yes, I know just one small piece of many) is the nice inflow vs. outflow and that 17 DTC on Fintel. Time will tell, could be a nice set up.
0 · Reply
Njdude
Njdude Sep. 12 at 7:10 PM
$VIR I just realized that we got fast track designation in June of 2024 so we are in our 15 month already. Google search said it takes 1 to 3 years for phase 3 trials but I couldn’t find anything on how long it takes with fast track. Either way we are almost half way to 3 years. Let’s hope for some good news soon.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 10 at 4:19 PM
$VIR we are actually up month to date by 20%, it would be nice to recover at 20% a month, imagine the effect of compounding at that rate.
0 · Reply
Njdude
Njdude Sep. 10 at 12:13 AM
$VIR anyone know how the fireside chat went today ?
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 8 at 10:41 AM
$VIR let’s smash $6 this week, we are definitely trying to build at the moment. I read yesterday about meme stocks such as Gamestore are starting to shoot up again, basically Reddit identifies stocks which are heavily shorted and advises it’s members to start buying & then the shorters have to close their positions creating massive bounces of up to 1200%. It happened to Vir years ago when the Reddit brigade & Robin Hood started buying up our shares & in minutes our price went up to $140 before quickly settling back, lets hope history repeats itself.
1 · Reply
Dunnieboy1
Dunnieboy1 Sep. 4 at 9:03 PM
$VIR SAN FRANCISCO, August 25, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. Just a reminder that Vir have used conferences in the past when releasing data.
0 · Reply
Mhand
Mhand Sep. 4 at 1:47 PM
$VIR And here comes the blatant manipulation.
1 · Reply
PCIntern
PCIntern Sep. 4 at 1:28 PM
$VIR in the past I have found that when you get this type of almost-surreptitious increase in the SP after months or years of moribund performance, you find out after the fact that “somebody knew something”. Here’s hoping….
0 · Reply
cosmo11777
cosmo11777 Sep. 4 at 10:19 AM
$VIR
0 · Reply
StocksNCash
StocksNCash Sep. 4 at 3:04 AM
$VIR chart looking strong. Looking to open a position
0 · Reply
GSP
GSP Sep. 3 at 11:56 PM
This $VIR chart looks primed for a breakout. .
0 · Reply
GSP
GSP Sep. 3 at 10:12 PM
$IMVT $KSS $SPY $VIR $WKSP
0 · Reply
lenten
lenten Sep. 3 at 9:19 PM
$SPY $KSS $IMVT $WKSP $VIR
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 3 at 8:15 PM
$VIR has dawn arrived🙏
0 · Reply
Josvan
Josvan Sep. 3 at 8:08 PM
$VIR Above 6 this will fly.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 3 at 7:16 PM
$VIR looks to me like Vir have been presenting their wares to the institution’s, 2 buy recommendations in a week & the important thing being investors have reacted to the recommendations. Perhaps confidence is growing from within Vir that the therapies will make it to market.
0 · Reply
VIR_Tical1
VIR_Tical1 Sep. 3 at 12:37 PM
$VIR Evercore ISI initiated coverage of Vir Biotechnology (VIR) with an Outperform rating and $12 price target The firm sees a “compelling asymmetric setup” for the shares. Investors are underappreciating how quickly the Vir story can turn around, the analyst tells investors in a research note. Evercore believes the company has a “differentiated” oncology pipeline and pivotal-stage rare disease asset with validated biology. However, the stock trade below its cash position, the firm points out.
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 2 at 2:07 PM
$VIR looks like were on the rise again, it would be nice to clear $5 and move on.
1 · Reply
Abovezero0000
Abovezero0000 Aug. 29 at 11:56 AM
$VIR will report a -$175M loss in Q3, if the company doesnt report any partnerships/data updates between now and then, then the price should continue to downtrend going into Q3.
1 · Reply
VIR_Tical1
VIR_Tical1 Aug. 28 at 11:45 AM
$VIR From SA 8.27.25 article: BofA sees more than $1B in unadjusted peak sales for the combination of tobevibart and elebsiran. Vir describes tobevibart as a "neutralizing monoclonal antibody that has been engineered for immune engagement" and elebsiran as a "small interfering RNA (siRNA) that is designed to enable targeted delivery to the liver and to reduce hepatitis B surface antigen." BofA boosted its probability of success for the HDV combo therapy to 55% from 40%. Analyst Alec Stranahan added that "there seems to be minimal value attributed to T-cell engager (TCE) oncology programs despite initial proof-of-concept data." Vir currently has three TCR programs in the clinic and "additional derisking data in the next 12-18 months" is possible, Stranahan noted, adding that these candidates could have combined unadjusted peak sales of greater than $4B.
2 · Reply